» Articles » PMID: 20737576

Defining the Course and Prognosis of Adults with Acute Lymphocytic Leukemia in First Salvage After Induction Failure or Short First Remission Duration

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2010 Aug 26
PMID 20737576
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide-ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics.

Methods: Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration <1 year were analyzed. Multivariate analyses for subsequent CR and survival were conducted.

Results: Seventy-five of 245 patients (31%) achieved CR. The median CR duration was 5 months, the median survival was 4.7 months. In multivariate analysis, independent poor prognostic factors for not achieving CR were age >55 years, bone marrow blasts ≥20%, and platelet count <75 × 10(9) /L. Variables that were associated independently with shorter survival were age >55 years, bone marrow blasts ≥20%, platelet count <75 × 10(9) /L, albumin level <3 g/L, and lactic dehydrogenase level ≥1000 IU/L. Patients who had ≥3 of the 5 adverse factors (45%) had a median survival of 2 to 3 months and CR rates of 8% to 15%. Achieving CR was associated independently with improved survival in a landmark multivariate analysis (P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03-0.72).

Conclusions: The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival.

Citing Articles

Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study.

Kazama H, Nishina S, Seto T Jpn J Clin Oncol. 2024; 54(7):778-786.

PMID: 38643356 PMC: 11228829. DOI: 10.1093/jjco/hyae047.


Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.

Kayser S, Sartor C, Giglio F, Bruno A, Webster J, Chiusolo P Haematologica. 2023; 109(5):1385-1392.

PMID: 38058184 PMC: 11063861. DOI: 10.3324/haematol.2023.284310.


Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.

Kantarjian H, Logan A, Zaman F, Gokbuget N, Bargou R, Zeng Y Ther Adv Hematol. 2023; 14:20406207231201454.

PMID: 37822571 PMC: 10563488. DOI: 10.1177/20406207231201454.


Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.

Shah B, Chen J, Wu J, Feng C, Zhou L, Park J Adv Ther. 2023; 40(12):5383-5398.

PMID: 37801234 DOI: 10.1007/s12325-023-02662-3.


Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis.

Yoon J, Kwag D, Lee J, Min G, Park S, Park S Ther Adv Hematol. 2023; 14:20406207231154713.

PMID: 36895914 PMC: 9989437. DOI: 10.1177/20406207231154713.


References
1.
Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006; 109(3):944-50. DOI: 10.1182/blood-2006-05-018192. View

2.
Pui C, Evans W . Acute lymphoblastic leukemia. N Engl J Med. 1998; 339(9):605-15. DOI: 10.1056/NEJM199808273390907. View

3.
Durrant I, Richards S, Prentice H, Goldstone A . The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001; 14(6):1327-52. DOI: 10.1016/s0889-8588(05)70189-1. View

4.
George S, Ochs J, Mauer A, Simone J . The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol. 1985; 3(6):776-81. DOI: 10.1200/JCO.1985.3.6.776. View

5.
OBrien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G . Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008; 113(11):3186-91. PMC: 4188532. DOI: 10.1002/cncr.23919. View